secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001193125-24-027504
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports Q1 revenue $2.1M, cash $40.6M; FDA clears IND for enobosarm with GLP-1 for weight loss
--------------------------------------------------------------------------------

- Net revenue $2.1M (down from $2.5M YoY); gross profit $1.2M (up from $0.7M).
- Cash $40.6M at Dec 31, 2023, bolstered by $35.2M net proceeds from public offering.
- FDA cleared IND for enobosarm in combination with GLP-1 drugs to preserve muscle during weight loss.
- Phase 2b obesity study to start by April 2024; top-line results expected by end of calendar 2024.
- Enobosarm for metastatic breast cancer funding-dependent; sabizabulin COVID program paused without external funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/0001193125-24-027504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312524027504/d671709d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-027504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer